Ortholevo, Inc.
Lynnfield, MA Doing business as Ortholevo Inc. Ortholevo
- UEI
- P3HTBAK4HNC4
- CAGE
- 7QPH2
- Primary NAICS
- 325412 Pharmaceutical Preparation Manufacturing
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- NAICS codes registered in SAM.gov
- SAM.gov registration date
- Physical address
- 6 Hart Rd, Lynnfield, MA 01940, USA
- Website
- ortholevo.com
- Employees
- 1-10
- Estimated annual revenue
- $0-$1M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Recent federal awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Late stage development of sustained-release relaxin for treating joint contracture - project summary/abstract shoulder… | National Insititue of Arthritis and Musculoskeletal and Skin Diseases | $2,004,864 | |
| A novel office-based injectable to treat duchenne-related fibrosis | Defense Health Agency | $675,447 | |
| Enabling studies for the treatment of frozen shoulder using relaxin - project summary/abstract frozen shoulder or… | National Insititue of Arthritis and Musculoskeletal and Skin Diseases | $4,188,580 |
About Ortholevo, Inc.
Ortholevo, Inc. is a corporate for-profit organization registered in SAM.gov since October 2016, specializing in developing advanced biotechnology solutions focused on treating fibrotic tissue conditions. The company appears to be primarily concentrated on developing innovative therapeutic approaches for joint-related medical conditions, with a particular emphasis on creating sustained-release pharmaceutical formulations targeting specific musculoskeletal disorders. As a registered federal grant recipient, Ortholevo has successfully secured multiple project grants from civilian and defense-related federal agencies, demonstrating its commitment to advancing medical research and developing novel treatment methodologies.
Ortholevo has received significant federal grant awards from agencies like the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) and the Defense Health Agency, focusing on developing injectable therapeutic solutions for conditions such as shoulder arthrofibrosis and Duchenne-related fibrosis. The company's primary research involves creating polymeric microparticle sustained-release formulations, specifically utilizing relaxin-2, a peptide hormone designed to address fibrotic tissue accumulation. Their most recent grant, awarded in August 2024 for $504,965, aims to develop a sustained-release relaxin formulation for treating shoulder contracture, with project goals including pilot-scale drug substance production, late-stage manufacturing, GLP toxicology studies, and regulatory strategy development for an IND submission. Previous grants, such as the R44AR079326 and W81XWH2110719, similarly focused on developing innovative treatment approaches for joint contracture and fibrosis-related conditions, demonstrating Ortholevo's consistent research trajectory in addressing complex musculoskeletal medical challenges.
Quick answers
What is Ortholevo, Inc.'s UEI?
Ortholevo, Inc.'s Unique Entity ID (UEI) in SAM.gov is P3HTBAK4HNC4.
What is Ortholevo, Inc.'s CAGE code?
Ortholevo, Inc.'s CAGE code is 7QPH2.
What is Ortholevo, Inc.'s primary NAICS code?
Ortholevo, Inc.'s primary NAICS code is 325412 (Pharmaceutical Preparation Manufacturing).
Where is Ortholevo, Inc. located?
Ortholevo, Inc.'s physical address in SAM.gov is 6 Hart Rd, Lynnfield, MA 01940, USA.
Is Ortholevo, Inc. registered in SAM.gov?
Yes. Ortholevo, Inc.'s SAM.gov registration is active through May 1, 2027.
What is Ortholevo, Inc.'s most recent federal award?
Ortholevo, Inc.'s most recent federal grant award is Late stage development of sustained-release relaxin for treating joint contracture - project summary/abstract shoulder… (SB1AR084380), from National Insititue of Arthritis and Musculoskeletal and Skin Diseases, on August 6, 2024.
On GovTribe
See Ortholevo, Inc.'s full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors